Chinatsu Mori

机构：Chugai Pharmaceutical Co., Ltd. (Japan)

发表论文 21 篇 · 总被引 170 次 · h-index 8

代表论文

• Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer (2022 · International Journal of Molecular Sciences · 被引 40)
• Early-onset pancreatic cancer: Clinical characteristics and survival outcomes (2022 · Pancreatology · 被引 31)
• Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer (2021 · Japanese Journal of Clinical Oncology · 被引 15)
• Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer (2022 · Internal Medicine · 被引 10)
• Diagnostic Yield of Serial Pancreatic Juice Aspiration Cytologic Examination With Brush Cytology for Pancreatic Ductal Stenosis (2022 · Pancreas · 被引 10)
• Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer (2022 · Japanese Journal of Clinical Oncology · 被引 9)